Chugai Pharmaceutical Co., Ltd. (4519) Earnings Call Transcript & Summary
October 27, 2026
Earnings Call Speaker Segments
Kae Miyata
executiveGood afternoon, everyone, and thank you so much for joining us today for the conference on the December third-quarter financial results for FY 2026, even with your busy schedules. I'll be serving as the moderator for today's session. My name is Miyata, and I'm with the IR Group. This session is being held on the Zoom webinar platform. As shown on page three of the presentation material, we've laid out the agenda for today. The presentation itself will be delivered in Japanese, but a simultaneous interpretation service into English is available. Should you want to follow along with the English translation, please choose your preferred language at the bottom of your screen. Once the presentation concludes, we'll move on to taking questions. The Q&A session is scheduled to run for 30 minutes. Throughout the presentation, all of your lines will remain muted. At this point, I'd like to welcome Okuda to walk us through the summary of the third-quarter results for FY 2026.
Osamu Okuda
executiveGood afternoon. I'm Osamu Okuda, President and CEO. Allow me to walk you through an overview of our results for the third quarter of fiscal 2026. Kindly turn to page five. During the third quarter, we achieved growth in revenue as well as in profit. Sales held up firmly in Japan and abroad, and other revenue likewise increased. We are progressing well relative to our full-year forecast and anticipate surpassing it. On the business side, progress has been made on developing the Hemlibra autoinjector, and we now anticipate that it will launch in Japan and globally in 2027. This September, three of our researchers received the Lasker Award. Moving forward, we will leverage our distinctive technologies and science in order to reinforce our drug discovery capabilities and to drive sustainable growth. Please turn to the following page. Next, I would like to explain what drove the rise in revenue. Revenue rose by ¥156.5 billion, an increase of 17.2%. Within the domestic market, notwithstanding adverse effects stemming from drug price revisions and the penetration of generics, sales climbed by ¥62.6 billion, supported by growth in both core and new products. Furthermore, front-loading of shipments to pharmaceutical wholesalers, as a transitional measure ahead of the operation of the next-generation core business infrastructure, helped boost net sales.
Osamu Okuda
executiveNow for overseas — even with the drop in export unit prices, higher export volumes plus the exchange rate effect mostly made up for it, giving us a ¥49.6 billion gain. Exports of Nemluvio for Galderma and Alecensa for Roche were notably higher. Other revenue rose ¥44.2 billion, driven by more royalty income from Hemlibra and Nemluvio, along with milestone income. Domestic sales, overseas sales, and other revenue were all up, so we achieved top-line growth. Now let me go to the next slide. I'd like to discuss receiving the Lasker Award. Hemlibra's creation came from a strong wish to ease the burden on hemophilia A patients and their families. I want to express my deep respect for the creativity and tireless effort of our researchers, who came up with the original idea of substituting Factor VIII function with a bispecific antibody and overcame many difficulties — such as molecular design and manufacturing technology development — to make it a reality. This journey embodies our frontier spirit of thinking for ourselves and continuously taking on unprecedented challenges. Moving forward, each of our researchers will carry on this spirit to further strengthen the drug discovery capabilities of the entire organization.
Osamu Okuda
executiveWith proprietary science and technology as our focus, we'll keep developing novel medicines and tie those efforts to growth that lasts. That brings my overview to a close.
Kae Miyata
executiveUp next, Tsukasa Kusano will bring you up to date on what's in our development pipeline for Q3 of FY 2026.
Tsukasa Kusano
executiveHi, I'm Kusano, and I lead the Project and Lifecycle Management Unit. My portion covers what's in the development pipeline for the third quarter of 2026. The following are the key topics for that third quarter. On approvals: Enspryng, which is one of our in-house products, won U.S. approval in thyroid eye disease — that's a label expansion. On filings: we submitted four projects. The first is Enspryng, submitted in Japan, the U.S., and Europe for MOG antibody-associated disease. In Japan it carries Sakigake designation, and in the United States it has priority review designation. Hemlibra: during August we submitted the autoinjector as an additional dosage form — more detail on that later. In Japan as well, Vabysmo was submitted for macular edema associated with non-infectious uveitis. We're moving forward steadily toward our record count of planned filings. On study initiations: Cevostamab began a Phase 3 trial in relapsed or refractory multiple myeloma. AQUA07 was discussed at the prior quarter's conference. Enobegrobart: as we disclosed on the Tokyo Stock Exchange on September 28th, we've decided to halt development in obesity. Once Roche returns the license, we'll begin preparing to restart in-house development for SMA, including out-licensing to third parties. On readouts: both Lunsumio and ceftobiprole hit their primary endpoints in Phase 3 interim analyses. Kindly see the next slide.
Tsukasa Kusano
executivePresentations at major medical conferences are shown. Later, I will go over the Phase 3 data for divarasib in second-line non-small cell lung cancer. For relapsed or refractory multiple myeloma, cevostamab holds orphan drug designation. On agreements and out-licensing: all three were previously disclosed in news releases. For AB351, an anti-dengue virus antibody, we signed an exclusive license agreement with GlaxoSmithKline covering development, manufacturing, and commercialization for flavivirus infections, including dengue fever. For SPYK04, a RAF-MEK molecular glue for solid tumors, we granted InxMed, based in Hong Kong, which has strength in oncology, exclusive rights to develop, manufacture, and distribute globally across all indications. Now, at the bottom of this page, our in-house DONC52 will be presented at the ICDS 2026 in mid-November. We will report Phase 1a/b results in celiac disease, along with biologic POC results from the Phase 1c study, which verified DONC52's mechanism of action in humans. Here are the key R&D milestones for 2026. Items underlined and/or in bold font are those that changed since the last earnings conference and are as I have described. The only remaining event I have not mentioned is the start of the next 007 Phase 3 pediatric study. Preparation is progressing smoothly. Next, I would like to introduce the development of the autoinjector formulation for Hemlibra.
Tsukasa Kusano
executiveSince Hemlibra launched, its effectiveness and safety profile have been seen in hemophilia A patients with a range of clinical backgrounds. By talking with the many stakeholders involved in hemophilia care, we've looked into new delivery devices so that patients can stay on treatment with greater ease. So, with the goal of easing the burden and worry that patients and families feel around preparing and operating injections, we've chosen to develop this autoinjector. In the course of development, we intend to establish appropriate dosages, lower the risk of needle sticks, and increase reassurance through a hidden needle design, while improving QOL by making it easy to use and shortening treatment time. We're targeting a launch in Japan and globally in 2027. In Japan, we finished the regulatory filing in August 2026, this year. Now I'll move on to the Phase 3 CRESCENDO-1 study results for divarasib. This trial enrolled previously treated patients with KRAS G12C-mutated, unresectable, advanced, and recurrent NSCLC, and the findings were given as a late-breaking abstract at the recent ESMO Presidential Symposium. At the same time, they appeared in the New England Journal of Medicine. The study pitted divarasib head-to-head against first-generation KRAS G12C inhibitors. Against those agents, divarasib showed superior efficacy.
Tsukasa Kusano
executiveTo start with the primary endpoint, PFS, or progression-free survival, there was a 42% reduction in the risk of disease progression or death. Also, for the key secondary endpoints of OS, overall survival, it lowered the risk of death by 44%. Divarasib reached a median OS of roughly 18 months, beating the 12 months seen with sotorasib and adagrasib. With divarasib, no new safety signals came up, and treatment-related adverse events that were frequent were mostly low-grade and manageable. On the basis of these results, we intend to file for approval in Japan before this year ends. KRAS G12C-mutated NSCLC is a rare disease, and we will push development forward so divarasib can be delivered as a new treatment option as quickly as possible. Finally, I'd like to show our projected submissions. Projects marked with a light blue star are newly added ones, and those marked with green stars have changes in their projected submission year. In light of project progress, trontinemab for Alzheimer's disease has been moved forward to 2028 from 2029 and beyond. For 2026, six additional projects are scheduled. We are working diligently toward filing for all of these projects. The following slides are attached as our reference materials, so please refer to them as needed. That concludes my presentation.
Kae Miyata
executiveAnd to wrap up, Taniguchi, our CFO, will take you through the consolidated results for Q3 2026, on a core basis.
Iwaaki Taniguchi
executiveHi, this is Taniguchi, the CFO. I'll now take you through the financial results for the third quarter, or through the third quarter, of fiscal 2026. P&L. Beginning with revenue, it was ¥906.8 billion, an increase of ¥112.2 billion, or 14.1%, versus a year ago. That's a plus of 19. 19.0. Core operating profit was ¥536.1 billion? I'd like to go through this in order. First of all, overseas sales climbed ¥49.6 billion, or 11%, to ¥500.5 billion. Both new products and mainstay products have performed well, and we've been able to absorb whatever changes had an impact through the price revision. We also replaced ERP, with go-live on October 13th. For several weeks before and after that, we had to halt shipments in Japan. In the third quarter, we shipped ahead of time, and that had an effect of about ¥30 billion. That's there, but even so, we believe we're seeing growth over previous quarters. Now overseas, in addition to main products for Roche, we have Nemluvio exports to Galderma, which are doing well, bringing it to ¥500.5 billion. That's ¥49.6 billion above last year, year-on-year, a plus of 11%.
Iwaaki Taniguchi
executiveAnd then there's royalty and milestone revenue, which totaled ¥161.3 billion — a positive ¥44.2 billion versus a year earlier. Beyond the royalty payment from Roche, over the cumulative nine months we've booked one-time revenue that includes royalty, so we've seen a substantial increase. Turning to costs: cost of sales came in at ¥314.3 billion, an increase of ¥51 billion, or 19.4%. That really mirrors the strong sales growth itself. The cost of sales ratio also moved because of shifts in product mix — specifically, domestic sales, where imported products carry a comparatively higher cost, made up a bigger portion. It rose 1.6 points to 34.7%. R&D expenses climbed as projects progressed quite nicely, reaching ¥141.2 billion, up ¥12.4 billion. On SG&A, we had new product launches plus promotional spending in the first quarter, and we also had enterprise tax and bonuses. Consequently, it reached ¥76.9 billion, an increase of ¥7.5 billion. As a result, operating profit rose ¥85.6 billion to ¥536.1 billion. Operating margin improved 0.8 points to 50.2%. Lastly, net income climbed to 384.7, 7% — a higher financial account balance amid rising interest rates drove this, surpassing the 19% increase in operating profit.
Iwaaki Taniguchi
executiveMoving to the following page, you can see the sales breakdown along with the changes. Beginning at the bottom with the dark blue segment, domestic oncology sales came in at ¥204.8 billion, an increase of ¥24.1 billion year-on-year, or 13.3%. The new product Lunsumio posted growth. So did Polivy, whose combination with Lunsumio received approval in March. Tecentriq likewise grew steadily, more than offsetting Perjeta's decline. In addition, Avastin kept falling as a result of the NHI price revision and generics. Specialty sales reached ¥201.1 billion, rising ¥38.5 billion or 23.6%. Besides the mainstay products Hemlibra, Vabysmo, and Enspryng, the new product Evrysdi also grew steadily. Overseas sales totaled ¥500.5 billion, up 49.6, with Hemlibra, Alecensa, and Actemra — all of these mainstay products — growing steadily. The following page shows the quarterly progress for Hemlibra and Actemra, our two largest export products, against the full-year outlook. For Hemlibra, at this point we expect full-year sales to come in line with the forecast. With the third quarter now complete, and for the fourth quarter as well, the export plan has already been fixed. If things proceed along this line, we expect to land very close to the full-year forecast. For Actemra, as shown on the right-hand side, sales through the third quarter stand at ¥121.7 billion, which is very, very close to our forecast of ¥130.8 billion.
Iwaaki Taniguchi
executiveAs of today, we anticipate that sales for the full year will in fact come in above the forecast by roughly ¥10 billion or more. Now, the breakdown of operating profit. Beginning on the left, this represents the variance versus the prior year. In Japan, sales volume rose considerably. That figure is ¥62.6 billion. A volume gain occurred, and it offset — more than offset — the price revision. Overseas, too, the number was ¥49.6 billion. We have observed a decline in export unit price. Yet we also saw sales growth in emerging countries, and that resulted in a lower unit price. We more than compensated for that through volume. We also had the foreign exchange effect, and it amounted to ¥49.6 billion. Other revenue likewise went up ¥44.2 billion, and that produced an increase of ¥85.6 billion. Next, the single-quarter changes. We saw operating profit rise in the third quarter. Behind that, we had the items I have listed. Beyond product mix, in Japan we also had what would have been recorded in the fourth quarter actually recorded in the third quarter. Regarding cost and expenses, we are observing changes as we had expected. This illustrates the revenue components by quarter.
Iwaaki Taniguchi
executiveOnce more, third-quarter sales have climbed sharply, as you can see—landing in the early ¥30 billions. Even setting that aside, we view this as an improvement over prior quarters. On this slide, you can see the nine-month, year-to-date progress versus the financial forecast for revenue and profit alike. The benchmark for the third quarter is 75%, but we've gone well beyond it. The domestic market in particular is performing strongly. That stems from shipments being front-loaded ahead of the ERP rollout. Relative to the progress achieved in 2025 up to now, ours has been greater. Versus the full-year forecast, there's a very strong likelihood we hit the full-year forecast figure. This next slide presents progress against the initial forecast by segment and by individual product. For the major products, sales progress is in fact running above last year's level. This page then shows how exchange-rate fluctuation compares with last year's actual rate. The Swiss franc stood at ¥171.62 last year and ¥184.21 this year, so the yen has depreciated this year by ¥13, i.e., 13. On the revenue side, that produced an impact of ¥40.6 billion in revenue and ¥26.6 billion in OP.
Iwaaki Taniguchi
executiveMoving on, the balance sheet position is shown on the following page. Total assets came to ¥2.3743 trillion, which is ¥94.3 billion lower than a year earlier. The primary driver was a reduction in cash stemming from the special dividend payout. Net assets rose by ¥62.8 billion, reaching ¥2.0885 trillion, since equity accumulated from profits outweighed the dividends paid. So although total assets fell, net assets edged up somewhat, pushing the equity ratio to 88%. On cash — I mentioned earlier that cash declined by ¥170 billion. The next page lays out where net cash stood at the close of last year. At the end of last year, cash and deposits amounted to ¥979.7 billion. Operating free cash flow over the past nine years came to ¥427.7 billion. We then paid tax, corporate tax, and the special dividend. That produced a decrease of ¥110.7 billion, since tax plus the special dividend together came to ¥869 billion. The following slide covers the gap between core-based financial figures and IFRS-based figures. We have depreciation on the intangible asset, the ERP introduction cost, and business restructuring cost. Every one of those items sits within the adjustment. The final page sets out, in list form, the CapEx plan that has already been approved.
Iwaaki Taniguchi
executiveThat's everything from my side. Thanks a lot.
Kae Miyata
executiveWe’re going to begin the Q&A portion now. Kusano, who leads our Marketing & Sales Division, will be joining us for questions as well. So that as many people as possible get a chance to ask something, we ask you to keep it to 2 questions per person. Thank you for helping with that. Also, please be aware that an audio recording of the questions will be put up on our website at a later date along with the presentation. Let me go over how to choose your language one more time. At the bottom of your screen, click the interpretation icon and pick Japanese or English. If you haven’t set this, you may not hear anything at all. So please make sure you select it. We’ll now take your questions. Please click the raise hand button at the bottom of the Zoom webinar screen. When your turn comes, we’ll call your name. Our secretariat will send you a request to unmute. Please unmute, give your company name and your name, and then ask your question. If you’d like to cancel your question, please click the lower hand button. Now, if you’re joining the Zoom webinar by phone, please press star, then nine. I’ll call your name.
Kae Miyata
executiveKindly give your name and organization, then your name once more, and pose your question after that. If you wish to cancel, press star followed by nine once more. I'd like to ask Mr. Matsubara of Nomura Securities to take the floor. Mr. Matsubara, are you able to hear us? We can't hear you. I'm not sure whether Matsubara-san can hear me. Can you hear me at this point? Can you hear me at this point? Yes. Yes, we can. Yes, this is Matsubara of Nomura Securities. My apologies for the technical trouble. My first question concerns the ¥30 billion tied to the ERP system replacement that showed up for domestic sales. Is that a one-time item? You have only one question? That was my first question.
Iwaaki Taniguchi
executiveRight, it's a one-time item only, and during the term it will get resolved in the fourth quarter. The third-quarter increase gets adjusted in the fourth quarter, and that's all. Thanks very much. My second question concerns GYM329. Why was it that no effects were shown for obesity? I was told previously that with neuromuscular disease, an increase in muscle volume won't directly bring about improvement in motor function. Could you describe whether any tendency toward improvement was seen?
Osamu Okuda
executiveThank you very much, Matsubara-san, for asking that. This concerns the results from the GYM329 study. The outcome of the Phase 2 MANATEE study, which was published for SMA patients, covered both ambulatory and non-ambulatory patients. A consistent efficacy across both groups was not something we could observe. Because of that, it led to discontinuation. That said, looking at the long-term data for both ambulatory and non-ambulatory patients, we were seeing a tendency toward improvement in motor functions. That is a little different. We believe there is a possibility that this efficacy can be verified by improving the Phase 3 study design. There are some differences there. Beyond longer-term administration and adjusted inclusion/exclusion criteria for Phase 3, and also reconsidering concomitant drugs, we may be able to verify the effect, and we might. In addition, I believe you are thinking about out-licensing. Are you actually in the process of negotiating, or are you still waiting for the PCA study? We're doing both. We are starting the study, and we also have third-party out-licensing under consideration.
Kae Miyata
executiveThen we move on to Mr. Seiki with UBS Securities. Hi there, this is Seiki speaking. Thanks so much for walking us through the presentation, and congratulations on the Lasker Award. I've got two questions for you. The first one concerns the Vabysmo royalty during the third quarter. In the kessan tanshin, you gave us the regional sales figures, and after running my own calculation, my sense is that the royalty comes to somewhere between ¥2 billion and ¥3 billion. Is that right?
Iwaaki Taniguchi
executiveTaniguchi here. Thanks for the question. Specifics aren't something we can share. There are various components you might factor into your math, but that sits within other revenue outside of Roche. Thank you. Next, regarding DONC52. On Friday, 20th of November, Phase 1c is expected to come out — that is, patient data is expected to come out. What type of data should we expect? For instance, VH/CD ratio or symptom score. Do you plan to disclose those?
Osamu Okuda
executiveThanks a lot for the question about DONC52. The Phase 1a, Phase 1b, and Phase 1c study results are assessing the safety, tolerability, and PK of DONC52. When gluten is ingested, that gluten intake triggers T-cell activation, and we'll be looking at how that gets suppressed. We'll also be sharing information related to biomarkers. Symptom-related information is not something we intend to present.
Kae Miyata
executiveThen we have Yamaguchi-san from Citi Group. Yes. Are you able to hear me at this point? Yes. I'm Yamaguchi with Citigroup Securities. My initial question overlaps a bit with what Matsubara-san asked before. It concerns the domestic Japanese sales that were brought forward. This has nothing to do with sales overseas. Only the wholesalers in Japan are involved. Also, you're showing sales, and there wasn't any rise in the costs associated with that? Thank you.
Iwaaki Taniguchi
executiveThis is Taniguchi speaking. Thanks for the question. This was a domestic-only event. Overseas business isn't involved at all. There's been no impact on the cost side. Sales are the only area affected. Thank you. Looking at sales, it appears there were increases or shifts of 5% to 6%. As for the progress rate, it looks flat across all products, it seems? We don't disclose a product-by-product breakdown, so I hope you'll understand. The early ¥30 billion figure applies to the total, and it isn't the case that certain products stood out or have stood out. It looks as though this growth is double digit, which means we could have pursued domestic. Yes, that's how I understand it. On my second question, which ties to the first: Vabysmo — you likely have your own forecasts, and I believe it's included in the royalty outside of Roche. The progress rate through Q3 seems lower than their forecast, and naturally there's Buvieo as well. There's this gap. I wonder whether this is in line with a forecast, or falling short of it? Thank you very much. I'd like to say it's more or less what we expected. Thank you very much.
Kae Miyata
executiveMany thanks. Our next question comes from J.P. Morgan Securities, Mr. Wakao. Please go ahead. Hello, this is Wakao with J.P. Morgan. My first question concerns the numbers, and I'd like to direct it to Taniguchi. In your explanation, you gave us the reason behind the outperformance in this third quarter, so thank you for that, but beyond that, on overseas export, I believe progress is quite strong at 117%. That reflects the good performance of Nemluvio. I would like to hear your outlook for the remaining three months. Then, on royalty, Roche and others, could you comment? It appears the royalty from Roche is progressing quite well. Non-Roche royalty doesn't seem to be progressing as well as Roche in terms of the progress.
Iwaaki Taniguchi
executiveThank you. Regarding Nemluvio, that sits within overseas others, and it appears in the appendix. When you look at others, through the third quarter, the progress versus the full-year forecast is quite good — it's coming along very well. For the fourth quarter, we've already built the export plan into our numbers. As things stand, we will probably hit the full-year forecast. What remains open is how large the upside might be. That I can't say. Sorry. Turning to royalty — with Roche, things are moving along nicely. Looking at Roche's already-published overseas revenue for the third quarter, it's progressing quite well. Non-Roche is likewise in line with what we expected. Thank you. Export others, I believe, would include Nemluvio. Versus the original forecast, are you seeing stronger demand? Have you gone past the shipment plan? Through the third quarter, exports don't occur at an even pace, but they are within our expectation. My second question is for the CEO. Your share price has been adjusted and the valuation is coming down. Your third quarter was strong, and the penetration of foundation plus the GYM329 obesity result did not meet the initial expectation, so the market is viewing your company rather pessimistically. Then for Vabysmo, royalty is tracking almost in line with your plan, and I think we can still look for good profit growth, including from the pipeline.
Iwaaki Taniguchi
executiveSo my question is this: what's your view on the pipeline, and if there are any favorable factors out there that could give a lift to your valuation and the stock price, I'd like to hear about them.
Osamu Okuda
executiveI appreciate the question. Regarding our share price, a number of factors come into play, and I don't have much to add on that front. The Vabysmo royalty is moving forward in line with what we planned. If you look at Chugai's pipeline, as you can see, it's quite an attractive one, and we have promising projects. What we can do is pursue those projects in good faith, grounded in the science. When it comes to drug discovery and research, generating new modality and launching new projects matters a great deal, and 2027 and '28 will be very important timing for us, since we have promising projects from which we expect to obtain data. Thank you. That's all from me.
Kae Miyata
executiveThen, from Morgan Stanley MUFG Securities, Muraoka-san, go ahead. Thanks. Appreciate the opportunity to pose some questions. This is Muraoka from Morgan Stanley. Every time we get to the third-quarter point I ask this, so I apologize for bringing it up again. It concerns what you're thinking about the coming year, the next term. According to the sell-side consensus we've received through IR feedback, you're looking for core profit of ¥800 billion. The higher profit doesn't bother me at all, but for the sell-side consensus on next term, could you give me a sense of whether you anticipate it coming in above or below, or any indications whatsoever, as far as you're able to say?
Iwaaki Taniguchi
executiveMuraoka-san, thanks for asking that. Yes, we're in the third quarter now, moving toward next year, and we fully get what you're driving at with the question. As for discussions regarding next year, there's very little we can say at this point. A conference is scheduled to take place right at the start of next year. I'd like to address next year once we're into it. Understood. Thank you. Yes, I understand. Let me move on to a different question, the second one. I understand that in July you set up an office for investment strategy. Why? You did mention that if attractive technologies exist, you would consider them. Again, the cash needs aren't that great, ¥8,700. As Wakao-san mentioned, the share price is, as you can see, in 2025, we received a big dividend. Are there any gifts to investors that we might expect, including with this investment strategy you have?
Osamu Okuda
executiveThank you, Muraoka-san, for raising that. Chugai wrote and disclosed its capital allocation policy roughly two years back. It rested on two main pillars: the first is returning value to shareholders, and the second is strengthening Chugai's drug discovery capability, along with bringing in assets — acquiring them — to lift value, corporate value. Those are the two routes. We want to find the optimal balance between them so that shareholders get their return while, at the same time, our new drug discovery capabilities are reinforced. Now, when it comes to introducing new assets, as many investors have noted, we consider this very important. Turning to open innovation, from the start of 2025 Top 5, we have been advancing this effort toward 2030. Setting up this new organization for strategic investment forms part of that open innovation strategy. The Chugai Venture Fund, launched in 2023, was aimed at early-stage startup ventures, investing in possible future collaboration. When the technology or science reaches maturity, we hope to proceed more earnestly into collaboration. We have a partnering office set up on the West Coast of the USA. We are aware that very strong academic institutions and universities exist on the West Coast, and we want to push research collaboration more strongly — that office was created for this purpose.
Osamu Okuda
executiveThat's only a starting point. Down the road, we aim to bring in new assets, and we're also looking at acquiring companies, and we want to build that kind of capability inside Chugai Pharmaceutical. The organization tasked with that is the strategic investment group. Right now they're working on putting together a policy for strategic investment, and in the end all of that will turn into concrete action once opportunities come into view. Thank you.
Kae Miyata
executiveThanks a lot. Up next we have Tony Ren from Macquarie Capital—please go ahead.
Tony Ren
analystHi there. Are you able to hear me?
Kae Miyata
executiveYeah, that's something we can do.
Tony Ren
analystThank you. Congratulations on receiving the Albert Lasker Award. My hope is that you will also be awarded the Nobel Prize. How should we view the gross profit margin for the Hemlibra autoinjector? Do you believe that, owing to the device, your gross profit margin would be lower? In addition, is there anything you can share regarding the injection volume and how long the autoinjector takes to deliver the drug, typically expressed in seconds? That is my first question. My other question concerns divarasib, the Phase 3 CRESCENDO-1 study that was presented at ESMO 2026. It was presented on the Sunday's Presidential Symposium 2. It was very well received. I just wanted to see whether you think the program for this drug in lung cancer would have an effect on your R&D budget. Thank you.
Osamu Okuda
executiveThanks a lot for that question. On the autoinjector side, the launch we're aiming for is 2027. Over in Japan, we've already submitted our approval filing. For markets outside Japan, we'll file as quickly as we can. As for how it affects the cost ratio,
Tsukasa Kusano
executiveNothing there is material. The autoinjector is extremely convenient and provides substantial added value, and it would let us keep profit at the present level. We do not anticipate any rise in the cost ratio because of the autoinjector. Let me now address the dose and the dosing time in seconds. Many thanks for your question. Turning to dosing volume, as I said, we filed this year in August, and dosing and administration fall under the drug review. At this moment, sorry, we are unable to disclose that to you. That covers dosing volume. As for dosing time, once the autoinjector is placed, everything should be complete within 10 seconds, through to completion of the dose. Previously, we required some preparation before the actual dosing. We had to go through several steps, but that preparation will no longer be needed. It will ease the burden on caregivers. Previously, with vial preparation, the total took five minutes, and we can certainly cut that time down. Now, on CRESCENDO-1, as you noted, we gave a presentation at the Presidential Seminar at ESMO, on the next-generation KRAS G12C inhibitor. This drug was compared head-to-head. It is the only global head-to-head comparison study.
Tsukasa Kusano
executiveWhen it comes to KRAS mutations, the G12C mutation stands out as among the most common. On a global basis, it represents 14% of NSCLC cases, and it is also linked to poor prognosis for patients. In our domestic market, roughly 4% to 5% of non-small cell lung cancer patients carry the G12C mutation. Domestically, we have around 100,000 patients. If you multiply that 4% to 5%, we arrive at 4,000 to 5,000 patients. Against existing therapies, we have been able to demonstrate superiority when it comes to OS and PFS. That came from a head-to-head comparison. Our sales expectations aren't something I can really discuss, but we believe this drug will have a big impact. That's all.
Kae Miyata
executiveThank you. Moving on, we have Hashiguchi-san from Daiwa Securities Company Limited. Please go ahead. Thank you. This is Hashiguchi from Daiwa Securities. My question also concerns the Hemlibra autoinjector dose. I realize you're unable to provide the specific volume in numerical terms, but we also recognize that it isn't weight-based, which was previously the method for selecting volume or dose. Assuming the dose is fixed, how would you address weight differences among children, adults, and adolescents? Will you establish a stepwise fixed dose, or how about the equivalence demonstrated in any studies versus the conventional weight-based dosing? If such a study has been conducted, when will data from it be published, and in what form?
Tsukasa Kusano
executiveThank you very much, Hashiguchi-san, for asking about the Hemlibra autoinjector. As you rightly noted, because it is an autoinjector, it is a single-use product, so that likely gives you some sense of it. Again, this ties to the filing and the review. How that compares on a weight basis, and what type of data is being gathered — all of it is connected to the review process. We would like to share that information, all of those relevant details, once the outcome of the review has been published. Thank you. Now, this is an autoinjector — could any patient freely adjust the volume according to his or her weight? To use the same volume as previously? What about that kind of autoinjector? My apologies. Once again, anything concerning dosage and administration — the regulators have instructed us very strictly that we are not permitted to disclose anything tied to the review. That information may only come after the review process has been completed and published.
Kae Miyata
executiveMuch appreciated. Our next question comes from Mr. Wada at SMBC Nikko Securities. Please go ahead. Hi there, this is Wada with SMBC Nikko Securities. About divarasib and the RAS development strategy, I'd like to understand the positioning better. For the G12C-mutated NSCLC patient group, you've shown good data — congratulations. I believe you've been developing OB-00. At ESMO, LUNA-18 was presented as a poster. Altogether you have 3 projects or development efforts underway, including OB-00 for the RAS-related mechanism. My first question: within the KRAS G12C space, where does OB-00 sit? Also, I think a presentation on LUNA-18 took place, and it demonstrated some dose dependency, and you've chosen to discontinue that development because of a safety issue. I'd like to know whether dose dependency was seen for efficacy as well as safety. For PD, you examined ERK, and it appears to enter the cell via oral administration and seems to have some anti-tumor effect, but I'd like to know whether dose dependency was observed or not.
Tsukasa Kusano
executiveThanks a lot for that question, Wada-san, about G12C and LUNA-18. So, turning to divarasib and OB-00, how would we differentiate their positioning? Divarasib is the inhibitor targeting the KRAS G12C mutation. We're discussing patients who carry G12C mutations, whereas OB-00 works as a pan-KRAS inhibitor. Beyond G12C, G12D, and G12V, we expect a range of other KRAS mutations could benefit from OB-00. Now, combining two RAS inhibitors is backed by a substantial body of scientific rationale. Broadly speaking, using them in combination represents one possible approach. At Roche, they hold several drugs in the KRAS and RAS space. Considering Chugai Pharmaceutical's role within the Roche Group, we have to figure out the optimal path forward. Regarding the LUNA-18 findings, no safety problem emerged for LUNA-18. We examined efficacy, and versus the competitors, we concluded that differentiating LUNA-18 would prove very difficult. That is the reason we halted its development. As you noted, raising the dose led to higher concentration. Oral observation and cell migration were indicated. As you mentioned, kinase signaling downstream and expression levels of multiple molecular messenger RNA tended to decline.
Tsukasa Kusano
executiveJust a moment. Then, regarding safety, we observed class-effective adverse events. These were dose-dependent. That’s everything from me. Thank you very much. That’s all.
Kae Miyata
executiveThanks so much. That's all the time we have for questions and answers. So we'd like to wrap up the Q&A portion now. That brings today's conference on the FY 2026 December Q3 financial results to a close. Should anything remain unanswered because we ran out of time, please reach out to our Corporate Communications Department. You'll find our phone number and email address on the last page of the presentation materials. Many thanks for being with us today.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Chugai Pharmaceutical Co., Ltd. transcript — plus 131,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Chugai Pharmaceutical Co., Ltd. earnings transcripts and 131,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Chugai Pharmaceutical Co., Ltd. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.